Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I 100% get it, but that’s just a simple reply regarding certain aspects of Delaware law may not be applied here. No need for some of the ridiculous comments.
Extremely sad to see the backlash against Weezuhl when he has provided a different opinion, but backed up. He has been a fantastic resource over the years. This board needs sound dialogue, not just hypers and naysayers grasping at straws.
At this rate if we get no news until end of June, those won’t be the last of them.
I was expecting the smaller FDA submissions to have been approved by now go get some momentum going.
Sounds like a Google error more than anything.
I wouldn’t say it was the best cc ever. It was the highest revenue reported, but that’s a big difference.
Going off anticipated FDA timelines doesn’t mean something actually happened. Minor amendments wouldn’t need to have a PR in case one was needed and would push Elite to back of line again.
Well, then Nasrat has one freaking huge basement that can hold 3,000+ people at once. I guess they must have all been minions.
“From 2004 - 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development.”
Still waiting on hearing about Purdue vs Accord next steps in near future.
You do mean other than the simple swallowing more pills option, which is how most people abuse pills.
Except he posted 30 times/day. Nice to not have to weed through that. I couldn’t block for some reason.
Thanks for insight, much appreciated.
That’s what I was hoping or if it does, there would likely be minimal impact from a clearing house standpoint. I just know Medicaid and other reimbursement transactions have stopped through Change Healthcare and other routes need to be set up to collect A/R, which can sadly take months to transition. A simply terrible situation for those impacted.
Will be interesting to see if Change Healthcare hack impacts Elite. Client I am at has 90% of their reimbursement flow through here. Pharmacies were impacted throughout nation and will be for few more weeks. Crazy situation for sure.
Heavy bag and never ending losses? Is that what one would expect for a company that has record revenues and profits quarter after quarter, year after year? Their pipeline is growing with several pending drugs, a couple very large opportunities. If this stock is a bag, it must be a bag full of gold based on what my account balance says by several factors vs prior year.
And it finally has been starting to. This is an OTC stock dude, not a stock in the Dow30.
Not necessarily. Share price rose real nice between Q2 to Q3. Just a little adjustment back. Doesn’t mean it was driven purely off Q3 results, but rather an over appreciation of the stock in general as growth isn’t quite as growth expectations were set really high during Q2 and sales were great, but not at expectations set. I think this is just a continuation of management’s poor communication strategy. Stock will take care of itself in time.
Next quarter should fare much better with full Q of Prasco.
That’s completely different. He didn’t personally profit from SequestOx situation. SequestOx was a management miss.
Yes, but not with the simple majority of outstanding shares, plus there’s a certain bias there too.
Your laughing meme is just validation of ignorance. It’s exactly what needed to happen, why SequestOx failed and why Elite pursued additional studies all at the expense of more dilution to shareholders. Not sure why that deserves a laugh…unless you holding a short position.
Just an FYI that getting board approval is not what your post says. I am no laywer, but in corp finance space we often work closely with internal and external legal counsel for contracts, partnerships, settlements, risks, etc. What I do know is that lawyers are masters at picking apart every single word and action. Each word has meaning. They are trained in this art. One cannot pretend that AI sources like ChatGPT are the end all. I don’t believe that for one moment. I will again say that I don’t think anything material will come of accusations presented here, but also that I would not be surprised if anything does. “If the glove does not fit, you must acquit.”
There have amazing powerful legal teams that have had incredible success in the courts to the public’s surprise. We’re watching one unfold now with the prior US President as loophole after loophole and pitting courts against each other are among the delay strategies.
Never underestimate a good lawyer.
We have similar number, nice accumulation.
In all reality I don’t expect anything material to come out of it. I hate the optics of Mikah and always have, but it is what it is. For now, I’ll continue to ride in the backseat as a shareholder.
I don’t ever recall a shareholder approval of such. :)
When is the last time you saw Mikah’s financials?
This is why I stopped watching this board. So many ridiculous and poisonous posters here.
There are many fantastic value added posters, but too many inexperienced couch quarterbacks that think they know everything when in reality they know nothing.
Yes, what don’t you get? Mikah has revenue flow from Adderall profit split. Since he is a one-person shop he almost has to outsource any benefit offered by Mikah to Elite. The waters do get muddy here, but using 3rd parties is logical.
Not necessarily. Mikah can be the coordinator of such. Doesn’t mean they are providing those services directly. Contractors, consultants, temp labor can all be coordinated through 3rd parties.
End of June is YE financials 10K
By me cash prices are as low as $0.44 per IR and $0.71 per XR pill. Cash price.
Most people have insurance so there’s the PBMs, discounting, rebates, etc. to add complexity.
Currently, Ritalin and Vyvanse are the most common Rx for ADHD in Israel.
Today’s session is a result of extremely poor ELTP communication framing up Q2 and Q3 financial results. Overall, Q3 results were good, but not nearly as good as management set expectations for. I’m guessing Q2 had quite a bit of initial fill quantities for new pharmacy partners + the actual small financial impact from the initial Prasco volume launch. Simply another reason to get someone involved in the IR conference call dialogue and communication strategy. Nasrat set high expectations in Q2 and then failed to meet the very same bar he set with actual results. Now is the long waiting game until end of June for YE 10K financials.
I think Elite will buy remaining ownership from Mikah within the next year. I believe the acceptable offer wasn’t a fixed $ amount, but rather a fair multiple based on recent performance so that the value will change over time. Just my guess. I think he gets a fair return from Elite and then enhancing the acquisition price for ELTP when it is time to sell - so a double benefit of sorts.
Based on Nasrat’s comments during Q2 dialogue, we should expect BE results to take place early first half if they expect a filing during 2024. However, BE results will only be made public if they are positive as mentioned during last call. They may have failed, but I doubt it.
Elite is valued as a separate entity, which it is. Nasrat may package both up, which I don’t think he will, but we would be completely blind to any Mikah valuation.
That’s authorized generic. This is also before all the new generic competition enters market.
Crazy article. Thanks for sharing. Goes to show the risks for opioid and CNS players.
Well, that’s not very likely, but at least we know who recently bought in.
That isn’t Dianne. It’s simply smaller outlets picking up on the news.
My state is just south of progressive, but highest tier 10% state tax. That will be one heck of a tax bill I owe, which will be higher than my remaining mortgage.